Provided by Tiger Trade Technology Pte. Ltd.

Apellis Pharmaceuticals Inc.

21.42
-0.7100-3.21%
Pre-market: 21.28-0.1400-0.65%08:41 EST
Volume:2.37M
Turnover:50.62M
Market Cap:2.74B
PE:119.00
High:22.40
Open:22.40
Low:20.94
Close:22.13
52wk High:30.48
52wk Low:16.10
Shares:127.83M
Float Shares:78.12M
Volume Ratio:1.07
T/O Rate:3.03%
Dividend:- -
Dividend Rate:- -
EPS(TTM):0.1800
EPS(LYR):0.1775
ROE:7.48%
ROA:3.53%
PB:7.40
PE(LYR):120.69

Loading ...

Apellis price target lowered to $35 from $39 at Cantor Fitzgerald

TIPRANKS
·
Jan 13

Wells Fargo Sticks to Its Buy Rating for Apellis Pharmaceuticals (APLS)

TIPRANKS
·
Jan 13

Apellis Pharmaceuticals Is Maintained at Buy by Needham

Dow Jones
·
Jan 13

Analysts’ Opinions Are Mixed on These Healthcare Stocks: Regeneron (REGN), Alkermes (ALKS) and Apellis Pharmaceuticals (APLS)

TIPRANKS
·
Jan 13

Apellis falls -17.3%

TIPRANKS
·
Jan 13

Apellis posts FY2025 U.S. net product revenues of USD 689 million with SYFOVRE generating USD 587 million

Reuters
·
Jan 12

Should You Be Concerned About Apellis Pharmaceuticals, Inc.'s (NASDAQ:APLS) ROE?

Simply Wall St.
·
Jan 09

S&P 500 Hits New Record Highs, Alphabet Dethrones Apple: What's Moving Markets Wednesday?

Benzinga
·
Jan 08

Apellis Pharmaceuticals Inc : Stifel Cuts Target Price to $48 From $55

THOMSON REUTERS
·
Dec 19, 2025

U.S. RESEARCH ROUNDUP-Carmax, Cintas, Nike

Reuters
·
Dec 19, 2025

Apellis Pharmaceuticals General Counsel David O. Watson Reports Sale of Common Shares

Reuters
·
Dec 19, 2025

Is Apellis Pharmaceuticals Attractive After Recent 26% Surge Despite Mixed Valuation Signals?

Simply Wall St.
·
Dec 13, 2025

Sobi Wins Positive CHMP Opinion for Aspaveli in Rare Kidney Diseases

Reuters
·
Dec 12, 2025

Apellis Reports Positive Phase 3 Results for Its Kidney Disease Treatment Empaveli

MT Newswires Live
·
Dec 04, 2025

Apellis Wins FDA Approval for EMPAVELI in Rare Kidney Diseases

Reuters
·
Dec 04, 2025

Assessing Apellis Pharmaceuticals (APLS) Valuation Following Five-Year SYFOVRE Efficacy Data in Geographic Atrophy

Simply Wall St.
·
Dec 03, 2025

Apellis Pharmaceuticals to Participate in Upcoming Investor Conferences

Reuters
·
Nov 25, 2025

Apellis Pharmaceuticals General Counsel David Watson Reports Sale of Common Shares

Reuters
·
Nov 18, 2025

H.C. Wainwright Sticks to Its Buy Rating for Apellis Pharmaceuticals (APLS)

TIPRANKS
·
Nov 15, 2025

This Undervalued Biotech Might Have Just Proven Its Star Drug's Staying Power

Benzinga_recent_news
·
Nov 13, 2025